These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 29437625)
21. Plasma and CSF pharmacokinetics of meropenem in neonates and young infants: results from the NeoMero studies. Germovsek E; Lutsar I; Kipper K; Karlsson MO; Planche T; Chazallon C; Meyer L; Trafojer UMT; Metsvaht T; Fournier I; Sharland M; Heath P; Standing JF; J Antimicrob Chemother; 2018 Jul; 73(7):1908-1916. PubMed ID: 29684147 [TBL] [Abstract][Full Text] [Related]
22. Cefotaxime dosage in infants and children. Pharmacokinetic and clinical rationale for an extended dosage interval. Kearns GL; Young RA; Jacobs RF Clin Pharmacokinet; 1992 Apr; 22(4):284-97. PubMed ID: 1606788 [TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics of antimicrobial drugs in the cerebrospinal fluid. Skopnik H; Heimann G Pediatr Pharmacol (New York); 1983; 3(3-4):313-20. PubMed ID: 6330656 [TBL] [Abstract][Full Text] [Related]
24. Population pharmacokinetics and dosing optimization of latamoxef in neonates and young infants. Qi H; Kou C; Qi YJ; Tang BH; Wu YE; Jin F; Luo XJ; Shen YH; Guo YJ; Qi X; Wang YC; Dong Q; Chen XK; Shi HY; Zheng Y; Zhao W; Shen AD Int J Antimicrob Agents; 2019 Mar; 53(3):347-351. PubMed ID: 30472290 [TBL] [Abstract][Full Text] [Related]
25. [Fundamental and clinical investigations of cefotaxime in neonates]. Hashira S; Koike Y; Fujii R Jpn J Antibiot; 1982 Jul; 35(7):1737-48. PubMed ID: 6294355 [TBL] [Abstract][Full Text] [Related]
26. Developmental Population Pharmacokinetics and Dosing Optimization of Cefepime in Neonates and Young Infants. Zhao Y; Yao BF; Kou C; Xu HY; Tang BH; Wu YE; Hao GX; Zhang XP; Zhao W Front Pharmacol; 2020; 11():14. PubMed ID: 32116695 [TBL] [Abstract][Full Text] [Related]
27. Population pharmacokinetics and dosing optimization of mezlocillin in neonates and young infants. Zhou J; Jiang L; Zhang ZL; Wang ZR; Zhang YX; Lin X; Tang BH; Yao BF; Guo ZX; Yang JJ; Van Den Anker J; Wu YE; Zhao W J Antimicrob Chemother; 2022 Jul; 77(8):2238-2244. PubMed ID: 35662337 [TBL] [Abstract][Full Text] [Related]
28. [Transferability of cefodizime to cerebrospinal fluid of rabbits with meningitis caused by Staphylococcus aureus]. Haruta T; Okura K; Kuroki S; Yamamoto H; Kobayashi Y Jpn J Antibiot; 1989 Jun; 42(6):1279-85. PubMed ID: 2795852 [TBL] [Abstract][Full Text] [Related]
29. NONMEM analysis in determining the tri-exponential disposition of cefotaxime: a method of evaluating serum and urinary phase I data. Weber W; Harnisch L; Zimmer M; Rokitta C; Mendes P Int J Clin Pharmacol Ther; 1995 Oct; 33(10):560-4. PubMed ID: 8574507 [TBL] [Abstract][Full Text] [Related]
30. Cerebrospinal fluid penetration after combined administration of cefotaxime and ampicillin to rabbits with staphylococcal meningitis. Kobayashi Y; Haruta T; Okura K J Antimicrob Chemother; 1984 Sep; 14 Suppl B():125-34. PubMed ID: 6094431 [TBL] [Abstract][Full Text] [Related]
32. [A preclinical and clinical study of cefmenoxime in newborns]. Hashira S; Nonaka C; Fujii R Jpn J Antibiot; 1989 Dec; 42(12):2607-16. PubMed ID: 2614917 [TBL] [Abstract][Full Text] [Related]
33. Optimal dose of cefotaxime in neonates with early-onset sepsis: A developmental pharmacokinetic model-based evaluation. Shang ZH; Wu YE; Lv DM; Zhang W; Liu WQ; van den Anker J; Xu Y; Zhao W Front Pharmacol; 2022; 13():916253. PubMed ID: 36160425 [No Abstract] [Full Text] [Related]
34. Pharmacokinetics of cefotaxime and its desacetyl metabolite in plasma and in cerebrospinal fluid. Beyssac E; Cardot JM; Colnet G; Sirot J; Aiache JM Eur J Drug Metab Pharmacokinet; 1987; 12(2):91-102. PubMed ID: 3691581 [TBL] [Abstract][Full Text] [Related]
35. Cefotaxime therapy. Evaluation of its effect on bacterial meningitis, CSF drug levels, and bactericidal activity. Mullaney DT; John JF Arch Intern Med; 1983 Sep; 143(9):1705-8. PubMed ID: 6311128 [TBL] [Abstract][Full Text] [Related]
36. [Pharmacokinetic study of cefotaxime in newborn infants and infants]. Bégué P; Safran C; Sarlangue J; Quinet B; Martin C Arch Fr Pediatr; 1985; 42(7):547-50. PubMed ID: 4083974 [TBL] [Abstract][Full Text] [Related]
37. Target attainment analysis and optimal sampling designs for population pharmacokinetic study on piperacillin/tazobactam in neonates and young infants. Chen Y; Lu J; Dong M; Wu D; Zhu Y; Li Q; Chen C; Li Z Eur J Clin Pharmacol; 2016 Dec; 72(12):1479-1488. PubMed ID: 27644691 [TBL] [Abstract][Full Text] [Related]
38. Microanalysis of beta-lactam antibiotics and vancomycin in plasma for pharmacokinetic studies in neonates. Ahsman MJ; Wildschut ED; Tibboel D; Mathot RA Antimicrob Agents Chemother; 2009 Jan; 53(1):75-80. PubMed ID: 18955527 [TBL] [Abstract][Full Text] [Related]
39. Single-dose plasma and cerebrospinal fluid pharmacokinetics of ceftriaxone in infants and children. Reed MD; Rekate HL; Aronoff SC; Myers CM; Blumer JL Clin Pharm; 1983; 2(6):558-63. PubMed ID: 6317277 [TBL] [Abstract][Full Text] [Related]
40. [Cerebrospinal fluid diffusion kinetics of cefotaxime and fosfomycin in Staphylococcus aureus meningitis with otorrhea]. Tremeaux JC; Portier H; Sautreaux JL; Pechinot A; Kazmierczak A Pathol Biol (Paris); 1984 Jun; 32(5 Pt 2):556-8. PubMed ID: 6087251 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]